<DOC>
	<DOC>NCT01561417</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this trial is to demonstrate bio-equivalence between the marketed activated recombinant human factor VII (NovoSeven®) (CP-rFVIIa) and a new formulation stable at 25°C (VII25).</brief_summary>
	<brief_title>Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Hemorrhagic Disorders</mesh_term>
	<mesh_term>Thrombasthenia</mesh_term>
	<criteria>Caucasian Body Mass Index (BMI) between 18 and 27 kg/m^2, both inclusive Good health as indicated by medical history, physical examination including vital signs and ECG, and clinical laboratory test results Smoke less than 10 cigarettes (or equivalent) per day Capable of giving written Informed Consent (IC) Evidence of clinically relevant pathology or potential thromboembolic risk based on medical and/or family history as judged by the Investigator Known history of atherosclerosis, arteriosclerosis, thromboembolic events or known high levels of Troponin I Known or suspected allergy to activated recombinant human factor VII or related products or any of the components of the formulation Overt bleeding, including from gastrointestinal tract Hepatitis (B or C) infection HIV (human immunodeficiency virus) infection</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>